The US Preventive Services Task Force recommends against initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) in adults 60 years or older. The decision to initiate low-dose aspirin use for the primary prevention of CVD in adults aged 40 to 59 years who have a 10% […]
Data extracted from a primary prevention trial showed that aspirin significantly increases overall gastrointestinal (GI) bleeding risk in the elderly. The trial was conducted throughout 2010–2017 (n=19 114) in community-dwelling persons aged ≥70 years with low-dose enteric-coated aspirin or placebo. Over a median follow-up of 4.7 years (88 389 person years), there […]
A nationwide Swedish cohort study suggests that in patients with chronic viral hepatitis, low-dose (75 mg or 160 mg) aspirin use was associated with a duration-dependent significantly lower risk of incident hepatocellular carcinoma and liver-related death than no use of aspirin, without a significantly higher risk of gastrointestinal bleeding. The […]
A randomized controlled trial in Australia suggested that a low dose metoprolol and aspirin for 6 weeks reduces physiological and psychological surrogate measures of cardiovascular risk in early bereavement. After assessment within 2 weeks of bereavement, spouses (n = 73) or parents (n = 12) of deceased (aged 66.1 ± 9.4 years, 55 females) were randomized […]
An UK multicenter, randomized, double-blind, placebo-controlled trial suggests that aspirin and omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) might have chemopreventive effect on colorectal adenomas. Between Nov 11, 2011, and June 10, 2016, 709 patients aged 55–73 years who were identified during colonoscopy as being at high risk were randomly […]